Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WSK-V102KF
- Development stage
- Phase 1
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**WSK-V102KF** is an investigational combined COVID-19 and influenza vaccine being evaluated in adults aged 18 years and older. The registered Phase 1 study assesses its safety and immunogenicity as a single combination vaccination product relative to separate COVID-19 and influenza vaccines. The vaccine platform, antigen composition, influenza strain coverage, SARS-CoV-2 variant coverage, adjuvant, dosage form, and route of administration have not been publicly specified in the identified registry record.
- Other names
- Westvac COVID-19 and Influenza Vaccine威斯克新冠流感疫苗
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on WSK-V102KF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WSK-V102KF.